Implementation of an Analgesia-Sedation Protocol Is Associated With Reduction in Midazolam Usage in the PICU

Pediatr Crit Care Med. 2021 Oct 1;22(10):e513-e523. doi: 10.1097/PCC.0000000000002729.

Abstract

Objectives: Examine the association of a revised analgesia-sedation protocol with midazolam usage in the PICU.

Design: A single-center nonrandomized before-after study.

Setting: PICU at a quaternary pediatric hospital (Boston Children's Hospital, Boston, MA).

Patients: Children admitted to the PICU who were mechanically ventilated for greater than 24 hours. The preimplementation cohort included 190 eligible patients admitted between July 29, 2017, and February 28, 2018, and the postimplementation cohort included 144 patients admitted between July 29, 2019, and February 28, 2020.

Interventions: Implementation of a revised analgesia-sedation protocol.

Measurements and main results: Our primary outcome, total dose of IV midazolam administered in mechanically ventilated patients up to day 14 of ventilation, decreased by 72% (95% CI [61-80%]; p < 0.001) in the postimplementation cohort. Dexmedetomidine usage increased 230% (95% CI [145-344%]) in the postimplementation cohort. Opioid usage, our balancing metric, was not significantly different between the two cohorts. There were no significant differences in ventilator-free days, PICU length of stay, rate of unplanned extubations, failed extubations, cardiorespiratory arrest events, and 24-hour readmissions to the PICU.

Conclusions: We successfully implemented an analgesia-sedation protocol that primarily uses dexmedetomidine and intermittent opioids, and it was associated with significant decrease in overall midazolam usage in mechanically ventilated patients in the PICU. The intervention was not associated with changes in opioid usage or prevalence of adverse events.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Analgesia*
  • Child
  • Humans
  • Hypnotics and Sedatives / adverse effects
  • Intensive Care Units, Pediatric
  • Midazolam* / adverse effects
  • Respiration, Artificial

Substances

  • Hypnotics and Sedatives
  • Midazolam